Abstract
Since several randomized controlled studies have demonstrated that neoadjuvant chemotherapy (NAC) was non-inferior to primary debulking surgery (PDS) with respect to survival in patients with advanced ovarian cancer, many patients are now treated with NAC followed by interval debulking surgery (IDS). We examined the actual status and effectiveness of treatment strategy using NAC followed by IDS in Japanese clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
